-+ 0.00%
-+ 0.00%
-+ 0.00%
Annovis Bio Receives Second Consecutive Positive Recommendation From Independent Data And Safety Monitoring Board For Its DUET-AD Phase 3 Trial In Early Alzheimer's Disease; Six-Month Topline Results On Track For March 2027
Share
Listen to the news

This 12-month review follows the DSMB’s positive 6-month feedback, which was announced in February 2026. The DSMB recommended that DUET-AD continue without modification, based on the data accumulated through September 22, 2026, from 861 patients at different stages of dosing.

DUET-AD (NCT06709014) remains on track, with last patient, last visit for the 6-month treatment period expected on December 31, 2026, database lock on February 8, 2027, and 6-month topline results in March 2027.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending